Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

SELL
$3.13 - $7.31 $3.76 Million - $8.77 Million
-1,200,000 Reduced 63.51%
689,451 $2.16 Million
Q4 2022

Feb 13, 2023

BUY
$6.39 - $8.8 $809,344 - $1.11 Million
126,658 Added 7.19%
1,889,451 $13.3 Million
Q3 2022

Nov 09, 2022

SELL
$7.99 - $10.75 $623,220 - $838,500
-78,000 Reduced 4.24%
1,762,793 $15.2 Million
Q2 2022

Aug 12, 2022

BUY
$4.58 - $17.13 $6.99 Million - $26.1 Million
1,526,181 Added 485.1%
1,840,793 $15.2 Million
Q1 2022

May 16, 2022

BUY
$12.3 - $18.33 $521,052 - $776,495
42,362 Added 15.56%
314,612 $5.23 Million
Q4 2021

Feb 11, 2022

BUY
$7.44 - $16.72 $1.47 Million - $3.3 Million
197,250 Added 263.0%
272,250 $4.55 Million
Q3 2021

Nov 15, 2021

SELL
$4.85 - $9.73 $347,648 - $697,446
-71,680 Reduced 48.87%
75,000 $648,000
Q2 2021

Aug 11, 2021

SELL
$4.93 - $6.46 $135,520 - $177,578
-27,489 Reduced 15.78%
146,680 $796,000
Q1 2021

May 14, 2021

BUY
$5.24 - $6.99 $205,245 - $273,791
39,169 Added 29.01%
174,169 $1.04 Million
Q4 2020

Feb 12, 2021

SELL
$4.77 - $6.58 $532,537 - $734,610
-111,643 Reduced 45.27%
135,000 $705,000
Q3 2020

Nov 12, 2020

SELL
$4.36 - $5.5 $411,278 - $518,815
-94,330 Reduced 27.66%
246,643 $1.19 Million
Q2 2020

Aug 12, 2020

SELL
$3.6 - $7.75 $424,490 - $913,833
-117,914 Reduced 25.7%
340,973 $1.77 Million
Q1 2020

May 14, 2020

BUY
$2.77 - $5.75 $843,830 - $1.75 Million
304,632 Added 197.49%
458,887 $2 Million
Q4 2019

Feb 14, 2020

BUY
$2.5 - $4.26 $15,407 - $26,254
6,163 Added 4.16%
154,255 $619,000
Q3 2019

Nov 12, 2019

BUY
$3.0 - $7.58 $444,276 - $1.12 Million
148,092 New
148,092 $486,000

Others Institutions Holding KZR

About Kezar Life Sciences, Inc.


  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $510M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Chi Advisors LLC Portfolio

Follow Chi Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chi Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chi Advisors LLC with notifications on news.